FindTrial
Sign In

GV20-0251

DRUG6 trials

Sponsors

GV20 Therapeutics, West China Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Adult Refractory CancerAdvanced Solid TumorsCarcinoma, Non-Small-Cell LungCholangiocarcinomaColorectal NeoplasmsCutaneous MelanomaEndometrial CancerEndometrial Carcinoma (EC)

Phase 1

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RecruitingNCT05669430
GV20 TherapeuticsCutaneous Melanoma, Endometrial Carcinoma (EC), Non-Small Cell Lung Cancer +4
Start: 2023-03-23End: 2027-09-05Target: 365Updated: 2025-02-13
Study of GV20-0251 in Participants With Solid Tumor Malignancies
RecruitingNCT07070518
GV20 TherapeuticsAdult Refractory Cancer, Endometrial Carcinoma (EC), HCC - Hepatocellular Carcinoma +6
Start: 2025-07-11End: 2028-09-16Target: 350Updated: 2025-12-03
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
RecruitingNCT07106827
West China HospitalCholangiocarcinoma, Endometrial Cancer, HCC - Hepatocellular Carcinoma +5
Start: 2025-09-04End: 2028-06-11Target: 10Updated: 2025-11-24
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
Not yet recruitingNCT07307053
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdvanced Solid Tumors, Metastatic Solid Tumors, Rare Malignant Neoplasm
Start: 2026-01-01End: 2031-01-31Target: 600Updated: 2025-12-29
GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study
RecruitingNCT07457281
West China HospitalHead and Neck Squamous Cell Carcinoma HNSCC
Start: 2026-04-01End: 2028-06-01Target: 9Updated: 2026-03-25

Phase 2

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Not yet recruitingNCT07623642
GV20 TherapeuticsCarcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Colorectal Neoplasms +8
Start: 2026-06-02End: 2029-08-15Target: 227Updated: 2026-06-08

Related Papers

Abstract CT001: Evaluation of pharmacodynamic and potential predictive biomarkers for GV20-0251, an anti-IGSF8 antibody, as monotherapy from ongoing Phase 1/2a study
Cancer Research2026-04-17
Preliminary monotherapy efficacy of novel immune checkpoint blockade GV20-0251 (anti-IGSF8) in advanced melanoma patients with primary resistance to anti-PD1.
Journal of Clinical Oncology2025-05-28
Abstract 3914: IGSF8 is a novel innate immune checkpoint and cancer immunotherapy target
Cancer Research2024-03-221 citations
505 IGSF8 is a novel innate immune checkpoint and cancer immunotherapy target
Regular and Young Investigator Award Abstracts2023-10-311 citations